Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 2/20 | 0.43 |
| ▸ | KDM1A | O60341 | 1/20 | 0.36 |
| ▸ | GABRP | O00591 | 2/20 | 0.32 |
| ▸ | GABRD | O14764 | 2/20 | 0.32 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.32 |
| ▸ | GABRB1 | P18505 | 2/20 | 0.32 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.32 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.32 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.32 |
| ▸ | GABRA3 | P34903 | 2/20 | 0.32 |
| ▸ | GABRA2 | P47869 | 2/20 | 0.32 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.32 |
| ▸ | GABRA4 | P48169 | 2/20 | 0.32 |
| ▸ | GABRE | P78334 | 2/20 | 0.32 |
| ▸ | GABRA6 | Q16445 | 2/20 | 0.32 |
| ▸ | GABRG1 | Q8N1C3 | 2/20 | 0.32 |
| ▸ | GABRG3 | Q99928 | 2/20 | 0.32 |
| ▸ | GABRQ | Q9UN88 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1320950 | 1.00 | CA1 (0.43) | CA1KDM1AGABRPGABRDGABRA1 | |
| SCHEMBL13219663 | 0.82 | CA1 (0.46) | CA1KDM1AGABRPGABRDGABRA1 | |
| SCHEMBL1320563 | 0.77 | ALDH1A1 (0.46) | ALDH1A1TDP1 | |
| SCHEMBL1320565 | 0.77 | ALDH1A1 (0.46) | ALDH1A1TDP1 | |
| SCHEMBL31531960 | 0.75 | PAOX (0.41) | ALDH1A1POLBTRPA1 | |
| SCHEMBL10817278 | 0.75 | — | — | |
| SCHEMBL10817279 | 0.75 | — | — | |
| SCHEMBL25722770 | 0.74 | CA1 (0.33) | CA1 | |
| SCHEMBL93311 | 0.72 | — | — | |
| SCHEMBL10813034 | 0.71 | CES1 (0.44) | CA1ALDH1A1POLBTRPA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8058447-B2 | 4-Chromenonyl-1,4-dihydropyridinecarbonitriles and the use thereof | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2011-11-15 | — | — | US | disclosed |
| US-8058447-B2 | 4-Chromenonyl-1,4-dihydropyridinecarbonitriles and the use thereof | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2011-11-15 | — | — | US | disclosed |
| US-8058447-B2 | 4-Chromenonyl-1,4-dihydropyridinecarbonitriles and the use thereof | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2011-11-15 | — | — | US | disclosed |
| EP-1926727-B1 | 4-CHROMENONYL-1,4-DIHYDROPYRIDINECARBONITRILES AND THE USE THEREOF | Bayer Pharma AG (DE) | 2011-09-14 | — | — | EP | disclosed |
| US-7989633-B2 | 4-Chromenonyl-1,4-dihydropyridines and their use | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-08-02 | — | — | US | disclosed |
| US-7989633-B2 | 4-Chromenonyl-1,4-dihydropyridines and their use | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-08-02 | — | — | US | disclosed |
| US-20100022484-A1 | 4-Chromenonyl-1,4-dihydropyridines and their use | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2010-01-28 | — | — | US | disclosed |
| US-20100022484-A1 | 4-Chromenonyl-1,4-dihydropyridines and their use | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2010-01-28 | — | — | US | disclosed |
| US-20090214675-A1 | 4-Chromenonyl-1,4-dihydropyridinecarbonitriles and the use thereof | BAYER HEALTHCARE AG (DE) | 2009-08-27 | — | — | US | disclosed |
| US-20090214675-A1 | 4-Chromenonyl-1,4-dihydropyridinecarbonitriles and the use thereof | BAYER HEALTHCARE AG (DE) | 2009-08-27 | — | — | US | disclosed |
| US-20090214675-A1 | 4-Chromenonyl-1,4-dihydropyridinecarbonitriles and the use thereof | BAYER HEALTHCARE AG (DE) | 2009-08-27 | — | — | US | disclosed |
| EP-1926727-A1 | 4-CHROMENONYL-1,4-DIHYDROPYRIDINECARBONITRILES AND THE USE THEREOF | Bayer HealthCare AG (DE) | 2008-06-04 | — | — | EP | disclosed |
| EP-1910329-A1 | 4-CHROMENONYL-1,4-DIHYDROPYRIDINES AND THEIR USE | Bayer HealthCare AG (DE) | 2008-04-16 | — | — | EP | disclosed |
| WO-2007025604-A1 | 4-CHROMENONYL-1,4-DIHYDROPYRIDINES AND THEIR USE | BAYER HEALTHCARE AG (DE) | 2007-03-08 | — | — | WO | disclosed |
| WO-2007025604-A1 | 4-CHROMENONYL-1,4-DIHYDROPYRIDINES AND THEIR USE | BAYER HEALTHCARE AG (DE) | 2007-03-08 | — | — | WO | disclosed |
| WO-2007009670-A1 | 4-CHROMENONYL-1,4-DIHYDROPYRIDINECARBONITRILES AND THE USE THEREOF | BAYER HEALTHCARE AG (DE) | 2007-01-25 | — | — | WO | disclosed |
| WO-2007009670-A1 | 4-CHROMENONYL-1,4-DIHYDROPYRIDINECARBONITRILES AND THE USE THEREOF | BAYER HEALTHCARE AG (DE) | 2007-01-25 | — | — | WO | disclosed |
| WO-2005087740-A1 | FLUORENONE 1, 4,-DIHYDROPYRIDIN DERIVATIVES | BAYER HEALTHCARE AG (DE) | 2005-09-22 | — | — | WO | disclosed |
| WO-2005087740-A1 | FLUORENONE 1, 4,-DIHYDROPYRIDIN DERIVATIVES | BAYER HEALTHCARE AG (DE) | 2005-09-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100022484-A1 | 4-Chromenonyl-1,4-dihydropyridines and their use | RYR1, RYR2, CACNA1S | CA1 4277/4885KDM1A 2180/4885GABRP 3165/4885 |
| US-20090214675-A1 | 4-Chromenonyl-1,4-dihydropyridinecarbonitriles and the use thereof | RYR1, TNNI3, RYR2 | CA1 4162/4885KDM1A 1981/4885GABRP 3256/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.